Cancer cells, beware! A groundbreaking study reveals a new mechanism that could revolutionize cancer treatment, offering a targeted approach to eliminate these rogue cells. Researchers from The University of Osaka, in collaboration with the Massachusetts Institute of Technology, have made a remarkable discovery about how our cells divide and, more importantly, what happens when this process goes wrong.
Accurate cell division is the cornerstone of a healthy body. But what if this process malfunctions? It can lead to chromosomal instability, a key characteristic of cancer. The team focused on chromosome alignment during cell division, a critical step often orchestrated by the kinetochore, a protein complex. However, the complex interplay of various proteins has made it challenging to understand the exact mechanisms at play.
Using a cutting-edge technique called a genome-wide CRISPR screen, the researchers zeroed in on the role of two motor proteins: KIF18A and CENP-E. They found that these proteins work together to ensure chromosomes align correctly. But here's where it gets controversial... When they inhibited both proteins simultaneously, they selectively killed cancer cells!
The researchers used a unique cell line with a partially defective kinetochore to screen for genetic weaknesses. They discovered that cells with a defect in the CENP-C gene (a gene related to kinetochore) died when the KIF18A gene was disrupted. Further investigation revealed that these cells also had reduced levels of another motor protein, CENP-E. This suggested that KIF18A and CENP-E cooperate to drive early-stage chromosome alignment.
The study showed that, in normal cells, if one protein's function is compromised, the other can often compensate. However, when both are impaired, chromosome alignment fails, leading to cell death. The team found that cancer cells sensitive to KIF18A inhibitors naturally have low levels of CENP-E. This is the critical detail!
And this is the part most people miss... The study suggests that measuring CENP-E levels could help identify cancers that respond well to drugs blocking KIF18A. Furthermore, combining drugs targeting both proteins might make cancer treatments significantly more effective.
Professor Tatsuo Fukagawa, the study's senior author, emphasized that these findings underscore the importance of basic research in developing targeted cancer therapies.
What do you think? Does this research open exciting new possibilities for cancer treatment? Do you think the focus on specific protein combinations is the future of cancer therapy? Share your thoughts in the comments below!
